[1]万 宇,邹云春,王 岚,等.视网膜母细胞瘤组织中NSUN2 mRNA，PRMT5 mRNA表达水平与临床病理学特征及预后的相关性研究[J].现代检验医学杂志,2025,40(04):61-66.[doi:10.3969/j.issn.1671-7414.2025.04.011]
　WAN Yu,ZOU Yunchun,WANG Lan,et al.Study on the NSUN2 mRNA, PRMT5 mRNA Expression Levels in Retinoblastoma Tissue and Their Correlation with Clinical Pathological Characteristics and Prognosis[J].Journal of Modern Laboratory Medicine,2025,40(04):61-66.[doi:10.3969/j.issn.1671-7414.2025.04.011]
点击复制

视网膜母细胞瘤组织中NSUN2 mRNA，PRMT5 mRNA表达水平与临床病理学特征及预后的相关性研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年04期
页码:
61-66
栏目:
论著
出版日期:
2025-07-15

文章信息/Info

Title:
Study on the NSUN2 mRNA, PRMT5 mRNA Expression Levels in Retinoblastoma Tissue and Their Correlation with Clinical Pathological Characteristics and Prognosis
文章编号:
1671-7414（2025）04-061-06
作者:
万 宇a，邹云春a，王 岚a，李 娜a，何艺岚a，王 淑b
（首都医科大学附属北京安贞医院南充医院a. 眼科；b. 儿科，四川南充 637000）
Author(s):
WAN Yua, ZOU Yunchuna, WANG Lana, LI Naa, HE Yilana, WANG Shub
(a.Department of Ophthalmology; b.Department of Pediatrics, Beijing Anzhen Hospital Affiliated to Capital Medical University Nanchong Hospital, Sichuan Nanchong 637000, China)
关键词:
视网膜母细胞瘤; NOP2/Sun RNA 甲基转移酶家族成员2; 蛋白精氨酸甲基转移酶5
分类号:
R739.7；R730.43
DOI:
10.3969/j.issn.1671-7414.2025.04.011
文献标志码:
A
摘要:
目的 探讨视网膜母细胞瘤（Rb）组织中NOP2/Sun RNA 甲基转移酶家族成员2（NSUN2）、蛋白精氨酸甲基转移酶5（PRMT5）表达水平及与Rb 患者生存预后的相关性。方法 选取2019 年2 月~2021 年2 月首都医科大学附属北京安贞医院南充医院诊治的84 例Rb 患者（Rb 组），以50 例正常视网膜组织为对照组。采用实时荧光定量PCR（qRT-PCR）检测视网膜组织中NSUN2 mRNA，PRMT5 mRNA 表达水平。Kaplan-Meier 曲线分析NSUN2 mRNA，PRMT5 mRNA 对Rb 患者预后的影响。COX回归分析影响Rb 预后的因素。结果 Rb 癌组织NSUN2 mRNA（3.11±0.42），PRMT5 mRNA（2.84±0.39）表达高于对照组（0.80±0.23，0.76±0.20），差异具有统计学意义（t=35.935，35.033，均P ＜ 0.001）。肿瘤直径≥ 20mm，未分化型及IIRC 分期D~E 期Rb 癌组织NSUN2 mRNA，PRMT5 mRNA 表达高于肿瘤直径＜ 20mm，分化型组织及IIRC 分期A~C 期，差异具有统计学意义（t=18.297，141.770，16.693；18.663，139.144，39.947，均P ＜ 0.001）。NSUN2 mRNA 高表达组三年无进展生存率低于低表达组（60.00% vs 88.64%），PRMT5 mRNA 高表达组三年无进展生存率低于低表达组（56.10% vs 93.02%），差异具有统计学意义（Log rankχ2=13.440，19.501，均P<0.001）。未分化型、IIRC 分期D~E 期、NSUN2 mRNA 高表达、PRMT5 mRNA 高表达是影响Rb 患者预后的危险因素（Waldχ2=5.923~7.161，均P ＜ 0.001）。结论 Rb 组织中NSUN2 mRNA，PRMT5 mRNA 表达升高，与肿瘤最大径、病理分型及IIRC 分期有关，可作为评估Rb 生存预后的肿瘤标志物。
Abstract:
Objective To investigate the expression of NOP2/Sun RNA methyltransferase family member 2 (NSUN2) and protein arginine methyltransferase 5 (PRMT5) in retinoblastoma (Rb) tissue and their correlation with the survival prognosis of Rb patients. Methods From February 2019 to February 2021,84 patients with Rb (Rb group） were selected from Beijing Anzhen Hospital Affiliated to Capital Medical University Nanchong Hospital, and 50 normal retinal tissues were used as control group. Real-time fluorescence quantitative PCR (qRT-PCR) was used to detect the levels of NSUN2 mRNA and PRMT5 mRNA in retinal tissues.Kaplan-Meier curve was used to analyze the effect of NSUN2 mRNA and PRMT5 mRNA on the prognosis of Rb patients.COX regression analysis was used to analyze the factors affecting the prognosis of Rb. Results The expression of NSUN2 mRNA (3.11 ± 0.42) and PRMT5 mRNA (2.84 ± 0.39) in Rb cancer tissues were higher than that in the control group(0.80±0.23,0.76±0.20), and the differences were statistically significant (t=35.935, 35.033, all P < 0.001）.The expression of NSUN2 mRNA and PRMT5 mRNA in Rb cancer tissues with tumor diameter ≥ 20mm, undifferentiated and IIRC stage D~E were higher than that in tumor diameter<20mm, differentiated tissues and IIRC stage A~C cancer tissues, and the differences were statistically significant (t=18.297,141.770,16.693;18.663,139.144,39.947, 均P<0.001). The 3-year progression-free survival rate in the high expression group of NSUN2 mRNA was lower than that in the low expression group (60.00 % vs 88.64 %）. The 3-year progression-free survival rate in the high expression group of PRMT5 mRNA was lower than that in the low expression group (56.10 % vs 93.02 %） (Log rank χ2= 13.440, 19.501, all P < 0.001）.Undifferentiated type, IIRC stage D-E stage, NSUN2 mRNA high, PRMT5 mRNA high were risk factors affecting the prognosis of Rb patients (Waldχ2=5.923~7.161, all P<0.001). Conclusion The expression of NSUN2 mRNA and PRMT5 mRNA in Rb tissues is increased, which is related to the maximum diameter of tumor, pathological classification and IIRC stage, and can be used as a tumor marker to evaluate the survival prognosis of Rb.

参考文献/References:

[1] KOOCHAKZADEH L, YEKTA A, HASHEMI H, et al. Epidemiological aspect of retinoblastoma in the world:a review of recent advance studies[J]. International Journal of Ophthalmology, 2023,16(6):962-968.
[2] 章晋伟, 曹刚琴, 汪建. 视网膜母细胞瘤组织中赖氨酸羟化酶2 表达及其对瘤细胞迁移和侵袭的影响[J].现代检验医学杂志,2022,37(3):105-109,161. ZHANG J W, CAO G Q, WANG J. Expression of procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 in retinoblastoma and its effect on tumor cell migration and invasion[J]. Journal of Modern Laboratory Medicine, 2022, 37(3): 105-109, 161.
[3] DUNKEL I J, PIAO J, CHANTADA G L, et al. Intensive multimodality therapy for extraocular retinoblastoma: a children’s oncology group trial (ARET0321)[J]. Journal of Clinical Oncology, 2022,40(33):3839-3847.
[4] LUO G Y, XU W W, CHEN X Y, et al. The RNA m5C methylase NSUN2 modulates corneal epithelial wound healing[J]. Investigative Ophthalmology & Visual Science, 2023,64(3):5.
[5] ZHANG G Z, LIU L W, LI J H, et al. NSUN2 stimulates tumor progression via enhancing TIAM2 mRNA stability in pancreatic cancer[J]. Cell Death Discovery, 2023,9(1):219.
[6] ICHIKAWA T, SUEKANE A, NAKAHATA S, et al. Inhibition of PRMT5/MEP50 arginine methyltransferase activity causes cancer vulnerability in NDRG2low adult T-cell leukemia/lymphoma[J]. International Journal of Molecular Sciences, 2024,25(5):2842.
[7] LIU M, YAO B, GUI T, et al. PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression[J]. Theranostics,2020,10(10):4437-4452.
[8] 中华医学会眼科学分会眼底病学组, 中华医学会儿科学分会眼科学组, 中华医学会眼科学分会眼整形眼眶病学组. 中国视网膜母细胞瘤诊断和治疗指南(2019 年)[J]. 中华眼科杂志, 2019, 55(10):726-738. Chinese Vitreo-Retina Society of Chinese Medical Association,Ophthalmology Group of Pediatrics Society of Chinese Medical Association, Oculoplastic and Orbital Disease Group of Chinese Ophthalmological Society of Chinese Medical Association. Chinese guidelines for diagnosis and treatment of retinoblastoma (2019)[J]. Chinese Journal of Ophthalmology, 2019,55 (10): 726-738.
[9] ATIMA M O, IDAKWO U, KOMOLAFE O, et al. Presentation pattern and survival rate of retinoblastoma following chemotherapy: a prospective study[J]. BMC Pediatrics, 2023,23(1):538.
[10] 胡娟娟, 王旭, 朱立新, 等. 头颈部鳞状细胞癌中Klotho 基因表达及其甲基化水平与LC3 和NSUN2基因表达的相关性[J]. 华中科技大学学报（医学版）,2020,49(3):255-259. HU J J, WANG X, ZHU L X, et al. Klotho gene expression and its methylation level are correlated with LC3 and NSUN2 gene expression in head and neck squamous cell carcinoma[J]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong, 2020, 49 (3): 255-259.
[11] ZUO S P, LI L, WEN X Y, et al. NSUN2-mediated m5C RNA methylation dictates retinoblastoma progression through promoting PFAS mRNA stability and expression[J]. Clinical and Translational Medicine, 2023,13(5):e1273.
[12] HU Y B, CHEN C B, TONG X Y, et al. NSUN2 modified by SUMO-2/3 promotes gastric cancer progression and regulates mRNA m5C methylation[J]. Cell Death & Disease, 2021,12(9):842.
[13] SEIGEL G M, ONWUMERE O, SAUANE M, et al. ALYREF/THOC4 expression and cell growth modulation in retinoblastoma[J]. Pathology, Research and Practice, 2024,260:155392.
[14] HUANG Y Y, LI X, WEI L, et al. NSUN2 relies on ALYREF to regulate Nrf2-mediated oxidative stress and alleviate Doxinduced liver injury[J]. Biology Direct, 2024, 19(1):32.
[15] CHEN H X, LIU H Y, ZHANG C X, et al. RNA methylation-related inhibitors: biological basis and therapeutic potential for cancer therapy[J]. Clinical and Translational Medicine, 2024, 14(4):e1644.
[16] FANG D, LAI Z G, WANG Y. Overexpression of biglycan is associated with resistance to rapamycin in human WERIRb-1 retinoblastoma cells by inducing the activation of the phosphatidylinositol 3-Kinases (PI3K)/Akt/Nuclear factor kappa B (NF-κB) signaling pathway[J]. Medical Science Monitor, 2019,25:6639-6648.
[17] LIU A Y, YU C X, QIU C, et al. PRMT5 methylating SMAD4 activates TGF-β signaling and promotes colorectal cancer metastasis[J]. Oncogene, 2023,42(19):1572-1584.
[18] JIANG Y, ZHENG G Y, SUN X T. PRMT5 promotes retinoblastoma development[J]. Human Cell,2023,36(1):329-341.
[19] SLOAN S L, BROWN F, LONG M, et al. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma[J]. Blood, 2023,142(10):887-902.
[20] XIE F, ZHANG H, ZHU K K, et al. PRMT5 promotes ovarian cancer growth through enhancing Warburg effect by methylating ENO1[J]. MedComm(2020), 2023,4(2):e245.
[21] YANG L, MA D W, CAO Y P, et al. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression[J]. Theranostics, 2021,11(8):3742-3759.
[22] JIANG Y S, YUAN Y Y, CHEN M, et al. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PDL1 expression[J]. Theranostics, 2021,11(18):9162-9176.

相似文献/References:

[1]章晋伟,曹刚琴,汪　建.视网膜母细胞瘤组织中赖氨酸羟化酶2表达及其对瘤细胞迁移和侵袭的影响[J].现代检验医学杂志,2022,37(03):105.[doi:10.3969/j.issn.1671-7414.2022.03.022]
　ZHANG Jin-wei,CAO Gang-qin,WANG Jian.Expression of Procollagen-lysine 2-Oxoglutarate 5-Dioxygenase 2 in Retinoblastoma and Its Effect on Tumor Cell Migration and Invasion[J].Journal of Modern Laboratory Medicine,2022,37(04):105.[doi:10.3969/j.issn.1671-7414.2022.03.022]
[2]罗　钢,蔡丽英,呙　明.视网膜母细胞瘤组织中miR-142的表达及对细胞增殖和侵袭力的影响[J].现代检验医学杂志,2022,37(03):144.[doi:10.3969/j.issn.1671-7414.2022.03.030]
　LUO Gang,CAI Li-ying,GUO Ming.Expression of miR-142 in Retinoblastoma Tissues and Influences on Cell Proliferation and Invasiveness[J].Journal of Modern Laboratory Medicine,2022,37(04):144.[doi:10.3969/j.issn.1671-7414.2022.03.030]
[3]罗 文,罗 钢,周玉玲,等.视网膜母细胞瘤患儿血清LncRNA-NEAT1 水平表达及对瘤细胞生物学功能的影响[J].现代检验医学杂志,2024,39(03):115.[doi:10.3969/j.issn.1671-7414.2024.03.019]
　LUO Wen,LUO Gang,ZHOU Yuling,et al.Expression of Serum LncRNA NEAT1 in Children with Retinoblastoma and Its Impact on the Biological Function of Tumor Cells[J].Journal of Modern Laboratory Medicine,2024,39(04):115.[doi:10.3969/j.issn.1671-7414.2024.03.019]

备注/Memo

备注/Memo:
基金项目：四川省卫生健康科研课题普及项目（编号：19PJ224）。
作者简介：万宇（1982-），男，硕士研究生，副主任医师，研究方向：眼底病、眼瘤，E-mail：18783983596@163.com。
更新日期/Last Update: 2025-07-15